title: Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
abstract: Neuropsychiatric symptoms are common in Alzheimer's disease (AD) and other neurodegenerative disorders. Recent progress has been made with clinical trials, advancing new therapies for psychosis in Parkinson's disease (PD), agitation in AD, and apathy in AD. Definitions have emerged for agitation and apathy in patients with cognitive impairment, facilitating recruitment of clinical trial populations. Progress in clinical trial design and the agents being assessed promise to advance therapies for disabling symptoms and improve quality of life for patients and caregivers.
authors.affiliation: Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA.
authors.forename: J
authors.initials: J
authors.lastname: Cummings
authors.affiliation: Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA.
authors.forename: K
authors.initials: K
authors.lastname: Zhong
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D057565:Apathy / Q000187:drug effects; D015283:Citalopram / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods; D003072:Cognition Disorders / Q000188:drug therapy / Q000453:epidemiology / Q000523:psychology; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology*; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D012107:Research Design / Q000639:trends; D035703:Therapies, Investigational / Q000379:methods / Q000639:trends*; D016896:Treatment Outcome; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D010880:Piperidines; D015283:Citalopram; D014508:Urea; C510793:pimavanserin